News & Updates

Show Multimedia Only
Ixekizumab effective for difficult-to-treat psoriatic arthritis

Ixekizumab effective for difficult-to-treat psoriatic arthritis

08 Dec 2021 byAudrey Abella

The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.

08 Dec 2021
Guselkumab yields durable benefit in biologic-naïve PsA patients

Guselkumab yields durable benefit in biologic-naïve PsA patients

23 Nov 2021

The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.

23 Nov 2021